The China Partnering Forum at AdvaMed 2016 Proved a Success with More Than 150 Partnering Meetings Held

FM_admin
FM_admin

The China Partnering Forum fostered partnerships among 100 companies and produced profound insights on healthcare cross-border activities from key industry players.

Last month, TPP Healthcare closed its second annual China Partnering Forum with 200+ panel attendees and 150+ partnering meetings. Held at the center of city Minneapolis during AdvaMed 2016, the China Partnering Forum drew in companies from the United States, China and Europe with a diverse industry background of digital health, medical device, imaging equipment and diagnosis.

TPP co-founder and managing partner, Tony Chu’s, thoughts: “It’s safe to say that this year’s forum was a success. Not only did the attendance this year remain high, but the quality of companies we brought significantly improved. We were privileged to host the likes of Feng Jiang, the CEO of China Association for Medical Devices IndustryDr. Manny Villafana, Founder of St. Jude’s; and Christopher McHan, President of Neosoft Medical Systems. At the end of the week, TPP gained valuable industry insight, new contacts and stronger partners onsite.”

TPP Healthcare’s classic one-on-one partnering event returned this year due to popular demand. This hallmarked TPP session allows companies and investors to actively exchange their views on cross-border transactions in the healthcare industry – as well as sign new deals. In two days alone, the one-on-one meetings successfully connected over 50 Chinese enterprises in 150+ meetings with North American and European healthcare companies.

Two educational panels at TPP’s China Partnering Forum at this year’s AdvaMed also garnered active audience participation in an open discussion on innovation and commercialization in both the United States and China. The panels examined the opportunities and obstacles for Medtech innovations, as well as how to attract Chinese investors to invest in cross-border Medtech products.

Key takeaways:

  • China healthcare industry is in urgent need of Medtech innovation;
  • The key to Medtech innovation is to create value through integrating advanced technology;
  • U.S. companies should extend their reach not only to China’s top-tier cities, but to second- and third-tier markets (innovation is craved everywhere);
  • China is an approachable, open marketspace – especially for cross-border medical devices;
  • Chinese investors prefer long-term value creation over short-term benefits.

TPP Healthcare’s next upcoming event will be held during the week of JP Morgan’s Healthcare Conference in San Francisco in early 2017. Stay tuned for details!